Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously approved by the boards
About UsEvolution Bioscience is a global consultancy firm, specialising in market intelligence, strategy formulation, technology transfer and commercialisation services, covering the full range of Biotechnology sectors.
Get In Touch
BROWSE NEWS BY INDUSTRY
Agricultural Technology Biopharma Bioproduction Biotech Cancer Immunotherapy Cell Therapy Chemicals CRO/CMO Diagnostics Drug Development Gene Therapy Genomics & Proteomics Informatics & Analytics Life Sciences Medical Devices Mergers Partnerships & Acquisitions Metagenomics Next Generation Sequencing Regenerative Medicine The Future of BioManufacturing
BROWSE NEWS BY COMPANY
2016 © Evolution Bioscience / Darwin Hutton Partners